Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gregory

Showing results (851-860 of 930) with videos related to

Pageof 93
Sort By:
Clinical Medicine Insights. Endocrinology and Diabetes|October 23, 2023
Lessons Learned From COVID-19 Lockdown: An ASPED/MENA Study on Lifestyle Changes and Quality of Life During Ramadan Fasting in Children and Adolescents Living With Type 1 DiabetesAmir Babiker, Nancy Samir Elbarbary, Bothainah Alaqeel, et al.
Leukemia|December 2, 2020
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trialJames Croft, Sidra Ellis, Amy L Sherborne, et al.
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.
British Journal of Haematology|March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study resultsGraham H Jackson, Gareth J Morgan, Faith E Davies, et al.
The European Respiratory Journal|July 4, 2020
SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resectionKevin N Franks, Lucy McParland, Joanne Webster, et al.
Nature Communications|April 24, 2015
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaBrian A Walker, Christopher P Wardell, Alex Murison, et al.
Brain Communications|March 30, 2022
Transactive response DNA-binding protein-43 proteinopathy in oligodendrocytes revealed using an induced pluripotent stem cell modelSamantha K Barton, Dario Magnani, Owen G James, et al.
Blood|October 31, 2018
Subclonal <i>TP53</i> copy number is associated with prognosis in multiple myelomaVallari Shah, David C Johnson, Amy L Sherborne, et al.
The Lancet. Haematology|October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Pageof 93

Showing results (851-860 of 930) with videos related to

Sort By:
Pageof 93
Clinical Medicine Insights. Endocrinology and Diabetes|October 23, 2023
Lessons Learned From COVID-19 Lockdown: An ASPED/MENA Study on Lifestyle Changes and Quality of Life During Ramadan Fasting in Children and Adolescents Living With Type 1 DiabetesAmir Babiker, Nancy Samir Elbarbary, Bothainah Alaqeel, et al.
Leukemia|December 2, 2020
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trialJames Croft, Sidra Ellis, Amy L Sherborne, et al.
The Lancet. Oncology|December 19, 2018
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Blood Cancer Journal|December 10, 2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trialJ R Jones, D A Cairns, W M Gregory, et al.
British Journal of Haematology|March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study resultsGraham H Jackson, Gareth J Morgan, Faith E Davies, et al.
The European Respiratory Journal|July 4, 2020
SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resectionKevin N Franks, Lucy McParland, Joanne Webster, et al.
Nature Communications|April 24, 2015
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaBrian A Walker, Christopher P Wardell, Alex Murison, et al.
Brain Communications|March 30, 2022
Transactive response DNA-binding protein-43 proteinopathy in oligodendrocytes revealed using an induced pluripotent stem cell modelSamantha K Barton, Dario Magnani, Owen G James, et al.
Blood|October 31, 2018
Subclonal <i>TP53</i> copy number is associated with prognosis in multiple myelomaVallari Shah, David C Johnson, Amy L Sherborne, et al.
The Lancet. Haematology|October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.
Pageof 93